Journal of Medical Economics
Volume 27, 2024 - Issue 1
Migraine
Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK
Karissa Johnstona Broadstreet Health Economics and Outcomes Research, Vancouver, CanadaCorrespondence[email protected]
https://orcid.org/0000-0003-4570-9972
https://orcid.org/0000-0003-4570-9972, Lauren C. Powella Broadstreet Health Economics and Outcomes Research, Vancouver, Canadahttps://orcid.org/0000-0002-4329-5166
https://orcid.org/0000-0002-4329-5166, Evan Popoffa Broadstreet Health Economics and Outcomes Research, Vancouver, Canadahttps://orcid.org/0000-0002-3233-3147
https://orcid.org/0000-0002-3233-3147, , Robert Pawinskic Pfizer Ltd, Tadworth, UKhttps://orcid.org/0009-0009-0769-6219
https://orcid.org/0009-0009-0769-6219, Aideen Ahernc Pfizer Ltd, Tadworth, UKhttps://orcid.org/0000-0002-8912-6237
https://orcid.org/0000-0002-8912-6237, Sam Largec Pfizer Ltd, Tadworth, UKhttps://orcid.org/0009-0008-9628-1922
https://orcid.org/0009-0008-9628-1922, Thang Trand Pfizer Canada, Kirkland, Canadahttps://orcid.org/0009-0006-7007-3661
https://orcid.org/0009-0006-7007-3661 & Aaron Jenkinsc Pfizer Ltd, Tadworth, UKhttps://orcid.org/0000-0001-9785-9388
https://orcid.org/0000-0001-9785-9388 show all